Indication

In combination with ipilimumab and 2 cycles of platinum-based doublet chemotherapy (PDC) is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2397
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
17 January 2022
SMC meeting date:
07 December 2021
Patient group submission deadline:
04 October 2021